The Effect of Sympathetic Modulation on Cerebral Vasospasm Secondary to Aneurysmal Subarachnoid Hemorrhage
Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · May 29, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring whether a procedure called spinal cord stimulation can help reduce blood vessel spasms that can occur after a brain aneurysm ruptures, known as aneurysmal subarachnoid hemorrhage. The goal is to see if adding this treatment to the usual care can improve outcomes for patients who experience these spasms, which can be serious.
To participate in the trial, individuals must be between the ages of 65 and 74, have been diagnosed with a severe type of brain bleed (Fisher grade 3 or 4), and be willing to follow the study guidelines. Participants will need to provide consent and be available for the duration of the trial. However, those who are too ill to undergo standard treatment or have certain types of aneurysms may not be eligible. If you decide to take part, you will receive the usual care for your condition along with the spinal cord stimulation procedure, with the hope of improving your recovery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Provision of signed and dated informed consent form
- • 2. Stated willingness to comply with all study procedures and availability for the duration of the study
- • 3. Diagnosed with Fisher grade 3 or 4 aneurysmal subarachnoid hemorrhage (1)
- • 4. Ability to undergo endovascular treatment of aneurysmal subarachnoid hemorrhage
- • 5. For females of reproductive potential: Negative pregnancy test at time of treatment
- • 6. Plan to undergo standard of care and follow-up
- Exclusion Criteria:
- • 1. Medically unfit to undergo endovascular treatment (e.g., Hunt Hess grade 5)
- • 2. Does not provide consent for the procedure.
- • 3. Posterior circulation aneurysmal subarachnoid hemorrhage.
- • 4. Initial aneurysm treatment after post bleed day 1
About University Of Alabama At Birmingham
The University of Alabama at Birmingham (UAB) is a prominent academic institution and research hub dedicated to advancing healthcare through innovative clinical trials. Renowned for its commitment to medical discovery and education, UAB conducts cutting-edge research across a wide array of disciplines, including oncology, cardiology, neurology, and public health. With a robust infrastructure for clinical research, UAB fosters collaboration among interdisciplinary teams, leveraging state-of-the-art facilities and resources to enhance the translation of scientific findings into effective treatments and interventions. As a leader in clinical research, UAB aims to improve patient outcomes and contribute to the broader medical community through rigorous trial design and implementation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Birmingham, Alabama, United States
Patients applied
Trial Officials
Jesse Jones, MD
Principal Investigator
University of Alabama at Birmingham
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported